Cell Transplant. 2013;22 Suppl 1:S83-91. doi: 10.3727/096368913X672154. Epub 2013 Aug 29.
Stroke is the third leading cause of death worldwide and a huge perpetrator in adult disability. This pilot clinical study investigates the possible benefits of transplanting multiple cells in chronic stroke. A total of 10 consecutive stroke patients were treated by combination cell transplantation on the basis of an intraparenchymal approach from November 2003 to April 2011. There were six males and four females. Their age ranged from 42 to 87 years, and the course of disease varied from 6 months to 20 years. Six patients suffered cerebral infarction, and four patients suffered a brain hemorrhage. The olfactory ensheathing cells, neural progenitor cells, umbilical cord mesenchymal cells, and Schwann cells were injected through selected routes including intracranial parenchymal implantation, intrathecal implantation, and intravenous administration, respectively. The clinical neurological function was assessed carefully and independently before treatment and during a long-term follow-up using the Clinic Neurologic Impairment Scale and the Barthel index. All patients were followed up successfully from 6 months to 2 years after cell transplantation. Every subject achieved neurological function amelioration including improved speech, muscle strength, muscular tension, balance, pain, and breathing; most patients had an increased Barthel index score and Clinic Neurologic Impairment Scale score. These preliminary results demonstrate the novel strategy of combined multiple cell therapy based on intraparenchymal delivery: it appears to be relatively clinically safe and at least initially beneficial for chronic stroke patients. This manuscript is published as part of the International Association of Neurorestoratology (IANR) supplement issue of Cell Transplantation.
中风是全球第三大致死原因，也是导致成年人残疾的主要原因。本研究旨在探讨脑内多细胞移植对慢性中风的潜在治疗效果。2003 年 11 月至 2011 年 4 月，10 例连续中风患者接受了细胞联合移植治疗。6 例为男性，4 例为女性，年龄 42-87 岁，病程 6 个月-20 年。6 例为脑梗死，4 例为脑出血。将嗅鞘细胞、神经前体细胞、脐带间充质干细胞和施万细胞分别通过颅内脑实质内植入、椎管内植入和静脉内给药等方式移植。采用临床神经功能缺损评分（Clinic Neurologic Impairment Scale，CIS）和日常生活活动能力量表（Barthel Index，BI）在治疗前和长期随访时分别进行独立、仔细的临床神经功能评估。细胞移植后 6 个月至 2 年对所有患者进行了成功随访。所有患者的神经功能均有改善，包括语言、肌力、肌张力、平衡、疼痛和呼吸等方面，大多数患者的 Barthel 指数和 CIS 评分均有所提高。初步结果表明，基于脑内给药的多细胞联合治疗策略具有较好的临床安全性，且对慢性中风患者具有潜在的治疗作用。本文发表于国际神经修复学会（IANR）细胞移植专刊。
